Perrigo's Opill Receives FDA OTC Approval, Reshaping Access and Regulatory Strategy in the U.S. Contraceptive Market
Opill Pioneers the U.S. OTC Oral Contraceptive Market
On July 13, 2023, the U.S. Food and Drug Administration (FDA) approved Opill (generic name: norgestrel 0.075mg) as an over-the-counter (OTC) daily oral contraceptive, available without age restrictions. Norgestrel, a synthetic progestin, acts as a progestogen receptor agonist, inhibiting ovulation and sperm transport. Initially approved as a prescription drug in 1973, it is now in the marketed phase. Perrigo Company plc (PRGO) launched Opill in the U.S. in March 2024, transforming access from a model requiring clinic visits and prescriptions to a direct-to-consumer purchase model.
Clinical Validation Behind the Unanimous Advisory Committee Decision
The FDA's Nonprescription Drugs Advisory Committee and the Obstetrics and Gynecology Devices Advisory Committee voted 17-0 in favor of Opill's OTC switch on May 10, 2023. Laboratoire HRA Pharma's sNDA 017031/S-041 included label comprehension testing and a real-use study involving 880 participants. The key considerations were whether adolescents and individuals with low literacy could independently apply the dosing instructions and contraindications. This is not a development to prove new contraceptive efficacy but rather a Rx-to-OTC switch program that validates the ability to safely select and take it daily at the same time without physician supervision.
NDA vs. Monograph: Different Economic Pathways
Opill was approved through a supplement to its existing New Drug Application (NDA), rather than through the OTC monograph process, and therefore does not qualify for the 18-month monograph exclusivity provided by the CARES Act. Enacted on March 27, 2020, the CARES Act introduced FD&C Act 505G and the OTC Monograph User Fee Act (OMUFA), streamlining the administrative process for monograph changes and providing 18-month exclusivity for certain innovative changes requiring human subject clinical data. However, new ingredients, indications, or prescription-to-OTC switches require product-specific NDA data, resulting in higher development costs but offering greater brand differentiation and first-mover advantages.
Convenience and Efficacy Compete in the Contraceptive Market
The U.S. contraceptive market is valued at approximately USD 7.3 billion in 2024, and the U.S. OTC drug market is projected to reach approximately USD 39.77 billion in 2025, positioning Opill at the intersection of these two large consumer healthcare segments. Direct competition comes from prescription progestin-only oral contraceptives and combined oral contraceptives, while long-acting reversible contraceptives (LARCs) include Bayer's (BAYN) Mirena (levonorgestrel, a progestogen receptor agonist) intrauterine device and Organon's (OGN) Nexplanon (etonogestrel, a progestogen receptor agonist) implant. Opill offers immediate access without a procedure but requires daily adherence, targeting a different consumer segment than the sustained efficacy of LARCs.
Commercial Data Reveals Opportunities and Challenges
As of 2024, Opill is available in over 65,000 U.S. retail locations, with a suggested retail price of USD 19.99 for a one-month supply and USD 49.99 for a three-month supply. Circana data indicates that weekly sales in 2025 have plateaued at approximately 17,000 one-month packs and 4,700 three-month packs. Perrigo's 2025 North America Women's Health revenue is USD 72.4 million, a decrease of 10.7% year-over-year. This decline reflects the initial distribution effect of USD 15.0 million during the 2024 Opill launch, highlighting that long-term value depends on repeat purchase rates and expanded insurance coverage rather than the initial approval itself.
Opill is the first OTC daily oral contraceptive approved and marketed in the U.S., removing prescription barriers in the USD 7.3 billion U.S. contraceptive market. The 2023 advisory committee's 17-0 decision provides a regulatory framework for subsequent Rx-to-OTC developers to design label comprehension and real-use studies. In the short term, Perrigo (PRGO) has secured distribution in over 65,000 stores and established first-mover brand recognition, but the 2025 sales plateau and 10.7% decline in Women's Health revenue demonstrate the challenge of converting initial inventory into sustained demand. Long-term competition will be driven by combined oral contraceptives and existing LARCs such as Bayer's Mirena and Organon's Nexplanon, requiring Opill to differentiate through convenience. In the USD 39.77 billion U.S. OTC market, the ability to distinguish between monograph 18-month exclusivity and product-specific NDA strategies is crucial for the value of future portfolios.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/how-drugs-are-developed-and-approved/over-counter-otc-nonprescription-drugs